Q3 2022 Coloplast A/S Earnings Call Transcript
Welcome to the Coloplast interim financial statements for 9M 2021, '22. (Operator Instructions)
With that, I'll hand the floor to our speakers. Please begin your meeting.
/-&
Good afternoon, and welcome to our Q3 '21/'22 Conference Call. My name Kristian Villumsen. I'm the CEO of Coloplast. And I'm joined by our CFO, Anders Lonning-Skovgaard; and our Investor Relations team. We'll start like we usually do with a short presentation by Anders and myself, and then open up for questions from you.
Please turn to Slide #3. In Q3, we delivered 8% organic growth and an EBIT margin before special items of 30%. We delivered a respectable return on invested capital of 26% after tax and before special items, impacted by the acquisition of Atos Medical. Reported growth in Danish kroner was 21%. Atos Medical contributed 9 percentage points to the reported growth and delivered double-digit underlying growth.
Before I dive into today's results, I'd
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |